Novartis sends second wagon after KRAS gold rush
Joining the barrage of companies digging headfirst into the newly opened KRAS mine, Novartis has announced a multiyear agreement with Sixth Element Capital and the UK Beatson Institute for Cancer Research to develop small molecules identified by the institute’s drug discovery unit.
The deal, whose specifics have not been disclosed, is the Swiss giant’s second KRAS collaboration since June, when Amgen electrified the field by revealing the first patient efficacy data from a therapy aimed at one of the most pervasive, oldest and evasive cancer mutation targets. In July, Novartis inked a low-money deal with Mirati Therapeutics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.